We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
The latest trading session saw Adma Biologics (ADMA - Free Report) ending at $19.98, denoting a +1.22% adjustment from its last day's close. This move outpaced the S&P 500's daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The the stock of infectious disease drug developer has risen by 12.8% in the past month, leading the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. It is anticipated that the company will report an EPS of $0.13, marking a 1200% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $107.25 million, reflecting a 59.41% rise from the equivalent quarter last year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Adma Biologics presently features a Zacks Rank of #2 (Buy).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 40.29. For comparison, its industry has an average Forward P/E of 22.26, which means Adma Biologics is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 34% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Gains As Market Dips: What You Should Know
The latest trading session saw Adma Biologics (ADMA - Free Report) ending at $19.98, denoting a +1.22% adjustment from its last day's close. This move outpaced the S&P 500's daily loss of 0.19%. At the same time, the Dow added 0.09%, and the tech-heavy Nasdaq lost 0.36%.
The the stock of infectious disease drug developer has risen by 12.8% in the past month, leading the Medical sector's gain of 1.44% and the S&P 500's gain of 2.06%.
The upcoming earnings release of Adma Biologics will be of great interest to investors. It is anticipated that the company will report an EPS of $0.13, marking a 1200% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $107.25 million, reflecting a 59.41% rise from the equivalent quarter last year.
Investors should also note any recent changes to analyst estimates for Adma Biologics. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Adma Biologics presently features a Zacks Rank of #2 (Buy).
Looking at valuation, Adma Biologics is presently trading at a Forward P/E ratio of 40.29. For comparison, its industry has an average Forward P/E of 22.26, which means Adma Biologics is trading at a premium to the group.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 85, this industry ranks in the top 34% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.